Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.33 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 2/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.30 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558929 | 0.81 | LRRK2 (0.45) | LRRK2CACNA1BPIK3CAMTORMAP4K1 | |
| SCHEMBL248191 | 0.79 | ZAP70 (0.42) | GCKATR | |
| SCHEMBL248167 | 0.76 | PIK3CA (0.46) | LRRK2PIK3CAMTORMAP4K1GAK | |
| SCHEMBL248529 | 0.74 | GCK (0.40) | PIK3CAMTORGCKCDK9 | |
| SCHEMBL248398 | 0.72 | DHFR (0.37) | P2RX3P2RX2ATRACVR1TGFBR1 | |
| SCHEMBL249137 | 0.69 | PDE10A (0.42) | LRRK2PIK3CAMTORMAP4K1MAP3K12 | |
| SCHEMBL5559601 | 0.68 | MAP3K12 (0.38) | LRRK2PIK3CAMTORMAP3K12 | |
| SCHEMBL14638686 | 0.67 | ALDH1A1 (0.38) | LRRK2 | |
| SCHEMBL5564246 | 0.65 | P2RX3 (0.40) | LRRK2CACNA1BPIK3CAMTORMAP4K1 | |
| SCHEMBL15202728 | 0.64 | PDGFRB (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | LRRK2 464/4885CACNA1B 4652/4885PIK3CA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.